🩺 Nephrologist @HospitalClinic. 🧑🏻🏫 Associate professor @CampusClinicUB👨🏻🎓MD, PhD. Nephro🫀 and 🏠 dialysis. 🎼Classical musician. 🥘Valencian.
Barcelona, España
Joined May 2011
- Tweets2.4K
- Following818
- Followers672
- Likes3.4K
José Jesús Broseta Monzó retweeted
In #ChronicKidneyDisease, the urinary albumin creatinine ratio and urinary protein creatinine ratio provided clinically similar risk prediction for kidney and cardiovascular outcomes in a large cohort with established disease.
Although the urinary albumin-creatinine ratio was more strongly associated with kidney failure statistically, it did not provide meaningfully better discrimination, reclassification, or decision support than the urinary protein-creatinine ratio.
ja.ma/47p22C3
José Jesús Broseta Monzó retweeted
🚨HD intermitente🆚continuas en paciente crítico
🆕ICRAKI trial👥535
☠️Mayor mortalidad a 90 días➡️
☠️HD intermitente 63,3%🆚CRRT 53,6% (HR 1,30)
👀Pero ojo
⚠️HD convencional de 4 h con +/- Kt/V 1.1🥴
💡¿Serían iguales los resultados con SLED?
👇🏼
shorturl.at/tQfhS
José Jesús Broseta Monzó retweeted
🩺Control intensivo de PA en ERC
Metaanálisis con 88.830 👥
Por cada ⤵️ de 10 mmHg de PAS➡️
✅Eventos CV🫀 ↓11% (RR 0.89)
✅Muerte x cualquier causa (RR 0,83)
✅Inicio de HD/TR (sin dif)
📌Prioriza el TA intensivo siempre q sea bien tolerado👌🏼
👇🏼
shorturl.at/Zwgsk
José Jesús Broseta Monzó retweeted
Proud to share our last publication in @JCM_MDPI: mdpi.com/4132034
HV-HDFOL: Does phenotype matter? #hemodiafiltration #HDFOL #nephrology
🫀🩺 ¿Anticoagularías a todos los pacientes con fibrilación auricular y enfermedad renal avanzada?
🎙️ En el episodio 7 de #CaReCAST abordamos:
💊 AVK vs ACOD
🩸 Ictus vs hemorragia
🔬 ¿Anticoagular en HD?
🫀 Cierre de orejuela y ablación
Porque no todo es blanco o negro.
🎧 ¡Ya disponible en Spotify, Apple Podcasts e iVoox!
🟢 Spotify: open.spotify.com/episode/40X…
🟠 iVoox: go.ivoox.com/rf/182010847
🔴 Apple Podcasts: podcasts.apple.com/es/podcas…
🔥 ¿Es la inflamación el próximo gran objetivo terapéutico en la ERC?
La respuesta en la nueva revisión en @RevistaNefrolog con @jlgorriz @JaimeMazonRuiz @beaff26 @mmvidas @aortznfr @jjcarrero1 #AleixCases
sciencedirect.com/science/ar…
@SENefrologia
José Jesús Broseta Monzó retweeted
📢 1-Y outcomes in 🇪🇸CardioRen
🔹 Kidney Function was associated with ⬆️events
🔹 Event rates were ⬇️than historical cohorts.
🔹 eGFR predicted mortality, but not the composite outcome.
🔹 Congestion and comorbidities ➡️key drivers of morbidity.
revespcardiol.org/en-prognos…
José Jesús Broseta Monzó retweeted
Risk Factors for Subsequent Recurrent, Relapsing, and Repeat Peritonitis in Peritoneal Dialysis
doi.org/10.1093/ckj/sfag352
José Jesús Broseta Monzó retweeted
Meta-analysis: In adults with and without #ChronicKidneyDisease, intensive blood pressure lowering reduced major cardiovascular events by 15% per 10-mm Hg lower systolic blood pressure.
ja.ma/4hO14Ea
ALT JAMA Cardiology original investigation: \"Intensive vs Standard Blood Pressure Lowering in People With and Without Chronic Kidney Disease: A Systematic Review and Meta-Analysis.\" Authors include Fotini Iatridi, Alistair J. Roddick, Natalie Staplin, and others.
José Jesús Broseta Monzó retweeted
💉Belatacept tiene indicación en trasplante renal🫘
⚠️Abatacept no
‼️Pero en esta cohorte:
✅rechazo 9,4%🆚9,5%
📌Belatacept ➡️💉IV mensual en H de día
📌Abatacept ➡️💉SC semanal en 🏠
Estamos mirando lo suficiente al abatacept en trasplante renal❓
👇🏼
shorturl.at/bSJ1w
José Jesús Broseta Monzó retweeted
Cardio-kidney-metabolic (CKM) syndrome is a common and serious combination of obesity, diabetes, kidney disease, and heart disease. #ASNCJASN #review highlights how team-based care can improve access to effective treatments and lead to better patient outcomes. kidney.pub/CJASN1143
José Jesús Broseta Monzó retweeted
🦠IBP en diálisis peritoneal
Target trial emulation en 11693👥
⚠️⤴️peritonitis (HR 1,53)
💀⤴️mortalidad (HR 1,55)
☠️⤴️mortalidad asoc a peritonitis (HR 1,39)
💡H2RA: tb ⤴️peritonitis, pero menos
📌Revisar indicación y deprescribir IBP innecesarios
👇🏼
shorturl.at/ojDDE
José Jesús Broseta Monzó retweeted
Como 🫁🔄🫘.... ¿Qué articulo hay que leer ?
1/5 🧵 La fístula funciona… ¿y el ventrículo derecho?
Una nueva perspectiva invita a mirar el impacto cardiaco del acceso vascular en hemodiálisis.
El protagonista: el ventrículo derecho (VD), muchas veces olvidado en nuestra evaluación.
José Jesús Broseta Monzó retweeted
Dialysis adequacy MUST move beyond urea kinetics, and some of us have stated this for years.
🫀The dominant threat is cardiovascular stress: volumes, electrolytes, arrhythmia, LV load, inflammation... Kt/V is not enough
#nephtwitter #nephX
academic.oup.com/ndt/advance…
José Jesús Broseta Monzó retweeted
La crisis de vivienda en España: lo que creo que puede funcionar para solucionarla... y lo que probablemente no sirva o sea directamente contraproducente. En siete minutos y medio.
Dentro video 👇
José Jesús Broseta Monzó retweeted
A Perspective on the Role of Nephrologists in the Cardio-Kidney-Metabolic Syndrome
bit.ly/47vv4jd (OPEN ACCESS)
ALT The roles for nephrologists within the CKM Framework across the spectrum of kidney diseases. The outer rim represents distinct subs-specialties within which nephrologists may integrate the CKM framework and vice-versa. Abbreviations: AKI= acute kidney injury; AKD = acute kidney disease; CKD = Chronic Kidney Disease; CKM = Cardiac Kidney Metabolic
José Jesús Broseta Monzó retweeted
CKM syndrome is rising fastest where resources are scarcest. A new #ASNCJASN #perspective calls for community-based care, integrated digital health systems, and outcome-driven payment models to deliver scalable, equitable care, especially in low- and middle-income countries. kidney.pub/CJASN1222
José Jesús Broseta Monzó retweeted
NEW Viewpoint: The clinician–artificial intelligence scientist: a proposed career pathway in medicine.
Read it here: thelancet.com/journals/landi…
